LUPIN Pharmaceuticals


lupinThe company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. It is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.

# Key Features
The company is the 3rd largest Indian pharmaceutical company by sales.
Lupin is a transnational pharmaceutical company with an annual turnover of USD 2.06 Bn.20% growth in revenue and profit.

Lupin is an innovation led transnational pharmaceutical company with an annual turnover of USD 2.06 Bn. It has a strong business model, the right business practices, like-minded people, a lucrative pipeline and investments in strategic growth. It is the 7th largest generic pharmaceutical company globally by market capitalization and the 10th largest generic pharmaceutical company globally by sales (Bloomberg, June 2015). Lupin is also the 6th largest pharmaceutical player in the US, the 3rd largest Indian pharmaceutical company by revenues and the 8th largest generic pharmaceutical company in Japan.
The company’s 48 per cent revenue is generated from advanced markets (i.e. US and Japan), 24 per cent from the domestic market, 19 per cent from the emerging markets and 6 per cent from API.
Forty six years on, what has stayed with the company is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people. The company today is a fully integrated pharmaceutical company with an unrivalled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than it has ever been. The company’s R&D has resulted in significant progress in its NCE program. The company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin’s world-class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realise its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa. The Drugs and products have reached over 100 countries in the world.
At Lupin, a culture of growth, of creative optimism, of caring for people and communities has been created. This is what has helped it innovate and deliver strong performance year after year consistently. Lupin is committed to care, to grow, to nurture and to share.

FacebookGoogle+TwitterWhatsApp